Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Ectopic ACTH-producing Tumors
NCT02780882Phase 2Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in ectopic adrenocorticotropic hormone syndrome (EAS), sponsored by Cedars-Sinai Medical Center. Planned start Dec 2015; status: withdrawn.
02
Drugs
pasireotide LAR
03
Conditions
ectopic adrenocorticotropic hormone syndrome (EAS)
Beyond the preview
Go deeper on NCT02780882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780882.